▶Macrolides(clarithromycin)are predicted to increase the
exposure toimatinib.oStudy
▶Macrolides(erythromycin)are predicted to increase the
exposure toimatinib.oTheoretical
▶Imatinibis predicted to increase the exposure tomidazolam.
Monitor side effects and adjust dose.rStudy
▶Imatinibis predicted to increase the exposure tomidostaurin.
oTheoretical
▶Mitotaneis predicted to decrease the exposure toimatinib.
Avoid.oStudy→Also seeTABLE 15p. 850
▶Imatinibis predicted to increase the exposure tonaloxegol.
Adjustnaloxegoldose and monitor side effects.oStudy
▶Netupitantis predicted to increase the exposure toimatinib.
oTheoretical
▶Nevirapineis predicted to decrease the exposure toimatinib.
oStudy
▶Imatinibis predicted to increase the exposure toolaparib.
Avoid moderate inhibitors of CYP3A4 or adjustolaparibdose.
oTheoretical→Also seeTABLE 15p. 850
▶Imatinibis predicted to increase the exposure toopioids
(alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and
adjust dose.oStudy
▶Imatinibis predicted to increase the exposure toopioids
(methadone, sufentanil).oTheoretical
▶Imatinibis predicted to increase the exposure tooxybutynin.
nTheoretical
▶Imatinibincreases the risk of hepatotoxicity when given with
paracetamol.rAnecdotal
▶Imatinibis predicted to increase the exposure topazopanib.
oTheoretical→Also seeTABLE 15p. 850
▶Pegaspargaseis predicted to increase the risk of
hepatotoxicity when given withimatinib.rTheoretical→
Also seeTABLE 15p. 850
▶Imatinibis predicted to increase the risk of bleeding events
when given withphenindione.rTheoretical
▶Imatinibis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(avanafil). Adjustavanafil
dose.oTheoretical
▶Imatinibis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(sildenafil). Monitor or
adjustsildenafildose with moderate inhibitors of CYP3A4,
p. 120.oStudy
▶Imatinibis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(tadalafil).rTheoretical
▶Imatinibis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(vardenafil). Adjust dose.
rTheoretical
▶Imatinibis predicted to increase the exposure topimozide.
Avoid.rTheoretical
▶Imatinibis predicted to increase the exposure toquetiapine.
Avoid.oStudy
▶Imatinibis predicted to increase the exposure toranolazine.
rStudy
▶Imatinibis predicted to increase the exposure toribociclib.
oStudy
▶Rifampicinis predicted to decrease the exposure toimatinib.
Avoid.oStudy
▶Imatinibis predicted to increase the exposure toruxolitinib.
oTheoretical→Also seeTABLE 15p. 850
▶Imatinibis predicted to increase the exposure tosaxagliptin.
nStudy
▶Imatinibis predicted to increase the exposure tosimeprevir.
Avoid.rStudy
▶Imatinibincreases the concentration ofsirolimus. Monitor and
adjust dose.oStudy
▶Imatinibis predicted to increase the exposure toSSRIs
(dapoxetine). Adjustdapoxetinedose with moderate inhibitors
of CYP3A4.oTheoretical
▶St John’s Wortis predicted to decrease the exposure to
imatinib.oStudy
▶Imatinibis predicted to increase the exposure tostatins
(atorvastatin). Monitor and adjust dose.rStudy
▶Imatinibis predicted to increase the exposure tostatins
(simvastatin). Use with caution and adjustsimvastatindose,
p. 134.rStudy
▶Imatinibis predicted to increase the exposure tosunitinib.
oTheoretical→Also seeTABLE 15p. 850
▶Imatinibis predicted to increase the concentration of
tacrolimus.rStudy
▶Imatinibis predicted to increase the exposure totaxanes
(cabazitaxel).oTheoretical→Also seeTABLE 15p. 850
▶Tedizolidis predicted to increase the exposure toimatinib.
Avoid.oTheoretical
▶Imatinibis predicted to increase the concentration of
temsirolimus.oTheoretical→Also seeTABLE 15p. 850
▶Imatinibis predicted to increase the exposure totofacitinib.
oStudy
▶Imatinibis predicted to increase the exposure totolterodine.
nTheoretical
▶Imatinibis predicted to increase the exposure totolvaptan.
Adjust dose.oStudy
▶Imatinibis predicted to increase the exposure totrazodone.
oTheoretical
▶Imatinibis predicted to increase the exposure toulipristal.
Avoid if used for uterinefibroids.oStudy
▶Imatinibis predicted to increase the exposure tovenetoclax.
Avoid moderate inhibitors of CYP3A4 or adjustvenetoclax
dose.rStudy
▶Imatinibis predicted to increase the exposure tovinca
alkaloids.rTheoretical→Also seeTABLE 15p. 850
▶Imatinibis predicted to increase the exposure tozopiclone.
Adjust dose.oStudy
Imidapril→see ACE inhibitors
Imipenem→see carbapenems
Imipramine→see tricyclic antidepressants
Indacaterol→see beta 2 agonists
Indapamide→see thiazide diuretics
Indometacin→see NSAIDs
Indoramin→see alpha blockers
Infliximab→see monoclonal antibodies
Influenza vaccine (live)→see live vaccines
Inotuzumab ozogamicin→see monoclonal antibodies
Insulins→seeTABLE 14p. 850 (antidiabetic drugs)
▶Fibratesare predicted to increase the risk of hypoglycaemia
when given withinsulins.oTheoretical
Interferon alfa→see interferons
Interferon beta→see interferons
Interferons→seeTABLE 15p. 850 (myelosuppression)
interferon alfa.interferon beta.peginterferon alfa..
▶Interferonsare predicted to slightly increase the exposure to
aminophylline. Adjust dose.oTheoretical
▶Interferon alfais predicted to increase the risk of peripheral
neuropathy when given withtelbivudine. Avoid.r
Theoretical
▶Peginterferon alfaincreases the risk of peripheral neuropathy
when given withtelbivudine. Avoid.rStudy
▶Interferonsslightly increase the exposure totheophylline.
Adjust dose.oStudy
Ipilimumab→see monoclonal antibodies
Ipratropium→seeTABLE 10p. 849 (antimuscarinics)
▶Beta 2 agonistsare predicted to increase the risk of glaucoma
when given withipratropium.oAnecdotal
Irbesartan→see angiotensin-II receptor antagonists
Irinotecan→seeTABLE 15p. 850 (myelosuppression)
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
toirinotecan. Avoid.rStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the risk of toxicity when given with
irinotecan. Avoid.oStudy
▶Cobicistatis predicted to increase the risk of toxicity when
given withirinotecan. Avoid.oStudy
▶Enzalutamideis predicted to decrease the exposure to
irinotecan. Avoid.rStudy
▶HIV-protease inhibitorsare predicted to increase the risk of
toxicity when given withirinotecan. Avoid.oStudy
▶Idelalisibis predicted to increase the risk of toxicity when
given withirinotecan. Avoid.oStudy→Also seeTABLE 15
p. 850BNFC 2018 – 2019 Imatinib—Irinotecan 937
Interactions|Appendix 1A1